Intech Investment Management LLC lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 81.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,803 shares of the biotechnology company's stock after selling 7,662 shares during the quarter. Intech Investment Management LLC's holdings in Repligen were worth $268,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans raised its stake in shares of Repligen by 240.5% during the 2nd quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company's stock valued at $75,866,000 after buying an additional 425,061 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Repligen by 21.0% during the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company's stock worth $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC raised its position in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company's stock valued at $119,363,000 after acquiring an additional 199,322 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock valued at $54,149,000 after acquiring an additional 121,305 shares during the period. Finally, First Turn Management LLC purchased a new stake in Repligen in the 3rd quarter worth approximately $13,202,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Price Performance
Shares of NASDAQ RGEN traded up $6.68 during midday trading on Friday, hitting $148.94. The stock had a trading volume of 271,660 shares, compared to its average volume of 659,621. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a 50 day simple moving average of $141.38 and a 200-day simple moving average of $142.15. The company has a market capitalization of $8.35 billion, a PE ratio of -384.48, a P/E/G ratio of 4.47 and a beta of 0.96. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm's revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.23 EPS. On average, sell-side analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.
Insider Activity
In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.20% of the company's stock.
Analyst Upgrades and Downgrades
Several research firms recently issued reports on RGEN. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price on the stock. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of "Moderate Buy" and a consensus price target of $190.25.
Check Out Our Latest Research Report on RGEN
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
